You are here
Providing Relief & Emergency Humanitarian Assistance - How We Respond
Block before Body
Every day, Pfizer colleagues around the world work collaboratively with governments, non-governmental organizations (NGOs), healthcare providers and payers to enable prevention and treatment of disease by making medicines and vaccines available to as many people as possible. Recognizing the critical need in settings requiring relief and emergency humanitarian assistance, Pfizer has a three part approach including product donations, cash grants and other access solutions.
Pfizer manufactures a range of products that have the potential to assist those in need. Most of Pfizer’s product donations are managed centrally and are focused on specific diseases and designed to address the needs of people in a coordinated manner. These programs are designed to provide underserved communities with access to important, potentially life-saving medicines and vaccines, without compromising quality or safety.
Pfizer’s approach to product donations is based on an expressed need. We work with a range of local and global partners, including governments, healthcare experts, and NGOs to understand the most pressing unmet medical needs and determine the most effective way for a donation to meet the needs of affected communities. To maximize the potential benefits to these communities, we work with our many partners to assess existing local government and NGO programs so that any donations we make effectively support ongoing initiatives. The in-country NGOs also provide general needs assessments, which permit us to respond to a country’s requests for aid, to maintain contact with organizations in the field, and to ensure we have the relevant information necessary to plan a medicine or vaccine donation.
Our response to a country’s needs involves a variety of different approaches, including providing our medicines and vaccines to medical missions, as well as pre-placing products so that needs may be met through a more immediate response, if relief and emergency humanitarian assistance is needed.
Pfizer also donates medicines and vaccines for research that help advance global health priorities. In addition, we routinely support the research of independent clinicians and Investigator-Initiated Research (IIR) organizations by providing funding or study product.
Examples of Pfizer donation programs include:
International Trachoma Initiative
Since 1997, as part of a global strategy towards attempting to eliminate blinding trachoma by the year 2020, Pfizer has worked with the International Trachoma Initiative (ITI), the World Health Organization (WHO), and more than 100 partners and governments. In the past two years, we have doubled the amount of antibiotics donated for trachoma elimination, scaling up from treating 50 million people a year to over 100 million in 2016. This initiative, one of the largest public-private partnerships in the world, reflects the work of multiple stakeholders and requires complex forecasting and supply chain management, product stewardship, and a comprehensive public health strategy at the country level.
As of September 2016, more than 580 million doses of Zithromax® (azithromycin) have been donated by Pfizer and shipped to more than 35 countries.
Diflucan Partnership Program
The Diflucan Partnership Program is designed to help provide treatment for AIDS-related infections in developing countries around the world where the prevalence of HIV/AIDS is greater than 1%. The program donates Diflucan® (fluconazole) for opportunistic fungal infections associated with HIV/AIDS (cryptococcal meningitis and esophageal candidiasis) to governments and NGOs.
Since 2000, the Diflucan Partnership Program has donated over 106 million Diflucan Treatments, to more than 6,000 sites, in 63 countries across Africa, Asia, the Caribbean, and Latin America.
In 2014, Pfizer entered into a two-year agreement with a humanitarian organization to donate Prevenar 13® (pneumococcal 13-valent conjugate vaccine) for people living in situations requiring relief and emergency humanitarian assistance.
Recognizing ongoing needs to provide relief and emergency humanitarian assistance, we continue to offer to expand upon past donation agreements, in a way that could enable immediate delivery of vaccines to partners working on the ground. To help ease potential logistics challenges where adequate cold chain storage is not available, Pfizer works with its partners to develop strategies for storage of doses prior to distribution.
Active discussions are always ongoing with other humanitarian organizations to determine if more doses of our vaccines are needed to help in situations requiring relief and emergency humanitarian assistance.
In an effort to reach as many people as possible, we support a number of organizations working on providing relief and emergency humanitarian assistance to address refugee crises. For example, in 2015 the Pfizer Foundation1 provided cash grants to the International Rescue Committee, Save the Children and Project Hope, all organizations working on the ground in Europe and the Middle East to provide health care and other critical support to vulnerable populations.
Additional Access Solutions for Humanitarian Organizations
When crises unfold, Pfizer aims to work closely with governments around the world and NGOs to help provide countries with access to our vaccines. We are engaged in discussions with our partners on potential new approaches to ensure as many people as possible have access to life-saving vaccines.
Pfizer welcomes a partnership approach with organizations known to have expertise in providing relief and emergency humanitarian assistance and vaccination programs, to help identify new access solutions for addressing situations as they arise.
For more information about the role of product donations, grants and other strategies, please see the below links:
- The Partnership for Quality Medical Donations (PQMD) is a unique alliance of non-profit and corporate organizations committed to bringing measurable health impact to under-served and vulnerable people through active engagement with global partners and local communities: http://www.pqmd.org/
- The London Declaration Uniting to Combat NTDs is a collective of invested, interested and dedicated partners, working to fulfil the London Declaration and unite in their efforts to support the achievement of the WHO 2020 goals in respect to 10 Neglected Tropical Diseases: http://unitingtocombatntds.org/resource/london-declaration
- Guidelines for medicine donations in emergencies have been developed by the World Health Organization (WHO) in cooperation with major international agencies active in humanitarian relief. The Guidelines for Medicine Donations was updated in 2010. http//www.immunize.org/who/ http://www.who.int/selection_medicines/emergencies/guidelines_medicine_donations/en/
1 The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc with distinct legal restrictions.